Abstract

An increasing need toward a more efficient expansion of adherent progenitor cell types arises with the advancements of cell therapy. The use of a dynamic expansion instead of a static planar expansion could be one way to tackle the challenges of expanding adherent cells at a large scale. Microcarriers are often reported as a biomaterial for culturing cells in suspension. However, the type of microcarrier has an effect on the cell expansion. In order to find an efficient expansion process for a specific adherent progenitor cell type, it is important to investigate the effect of the type of microcarrier on the cell expansion. Human periosteum-derived progenitor cells are extensively used in skeletal tissue engineering for the regeneration of bone defects. Therefore, we evaluated the use of different microcarriers on human periosteum-derived progenitor cells. In order to assess the potency, identity and viability of these cells after being cultured in the spinner flasks, this study performed several in vitro and in vivo analyses. The novelty of this work lies in the combination of screening different microcarriers for human periosteum-derived progenitor cells with in vivo assessments of the cells’ potency using the microcarrier that was selected as the most promising one. The results showed that expanding human periosteum-derived progenitor cells in spinner flasks using xeno-free medium and Star-Plus microcarriers, does not affect the potency, identity or viability of the cells. The potency of the cells was assured with an in vivo evaluation, where bone formation was achieved. In summary, this expansion method has the potential to be used for large scale cell expansion with clinical relevance.

Highlights

  • The rising amount of research toward cell therapies is translated in the increasing amount of registered clinical trials on ClinicalTrials.gov of which currently 1409 trials use adult mesenchymal stem/stromal cells (MSC) as a therapeutic cell source

  • HPDCs are valuable in skeletal tissue engineering for the regeneration of defects in long bones, as the periosteum is the main source of the cells involved in the callus formation during facture healing (Nilsson Hall et al, 2020)

  • We investigated the influence of commercial microcarrier types for the expansion of human periosteum-derived cells (hPDCs) in an human platelet lysate (hPL) supplemented medium composition

Read more

Summary

Introduction

The rising amount of research toward cell therapies is translated in the increasing amount of registered clinical trials on ClinicalTrials.gov of which currently 1409 trials use adult mesenchymal stem/stromal cells (MSC) as a therapeutic cell source. Microcarrier Screening for Dynamic Expansion from the human periosteum due to their benefits in skeletal tissue engineering This periosteum is a thin vascular membrane around most bones, situated between the cortical bone and the covering soft tissue and consists of an outer fibrous layer and an inner cambium layer containing adult mesenchymal progenitor cells (Allen et al, 2004). These human periosteum-derived cells (hPDCs) have similar characteristics as adult mesenchymal stromal cells (MSCs). The outcomes of these commercial bone void fillers remain unpredictable (Slevin et al, 2016)

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call